000285353 001__ 285353
000285353 005__ 20260225104924.0
000285353 0247_ $$2doi$$a10.1038/s41591-025-04080-0
000285353 0247_ $$2pmid$$apmid:41491101
000285353 0247_ $$2pmc$$apmc:PMC12920126
000285353 0247_ $$2ISSN$$a1078-8956
000285353 0247_ $$2ISSN$$a1546-170X
000285353 037__ $$aDZNE-2026-00219
000285353 041__ $$aEnglish
000285353 082__ $$a610
000285353 1001_ $$0P:(DE-2719)9003257$$aHuber, Hanna$$b0$$eFirst author
000285353 245__ $$aA minimally invasive dried blood spot biomarker test for the detection of Alzheimer's disease pathology.
000285353 260__ $$a[New York, NY]$$bSpringer Nature$$c2026
000285353 3367_ $$2DRIVER$$aarticle
000285353 3367_ $$2DataCite$$aOutput Types/Journal article
000285353 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1772012822_9598
000285353 3367_ $$2BibTeX$$aARTICLE
000285353 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285353 3367_ $$00$$2EndNote$$aJournal Article
000285353 520__ $$aBlood biomarkers have emerged as accurate tools for detecting Alzheimer's disease (AD) pathology, offering a minimally invasive alternative to traditional diagnostic methods such as imaging and cerebrospinal fluid (CSF) analysis. Yet, the logistics surrounding venipuncture for blood collection, although considerably simpler than the acquisition of imaging and CSF, require precise processing and storage specific to AD biomarkers that are still guided by medical personnel. Consequently, limitations in their widescale use in research and broader clinical implementation exist. The DROP-AD project investigates the potential of dried plasma spot (DPS) and dried blood spot (DBS) analysis, derived from capillary blood, for detecting AD biomarkers, including phosphorylated tau at amino acid 217 (p-tau217), glial fibrillary acidic protein and neurofilament light. Here, 337 participants from 7 centers were included, with 304 participants providing paired capillary DPS or DBS and venous plasma samples. We observed strong correlations between DPS p-tau217 and venous plasma p-tau217 (rS = 0.74, P < 0.001). DPS p-tau217 progressively increased with increasing disease severity, and showed good accuracy in predicting CSF biomarker positivity (area under the curve = 0.864). Similarly, we demonstrated the successful detection of glial fibrillary acidic protein and neurofilament light with strong correlations between DBS and DPS, respectively, using paired venous plasma samples. Notably, the method was also effective in individuals with Down syndrome, a population at high genetic risk for AD but in whom standard blood sampling by venipuncture may be more complicated, revealing elevated biomarkers in those with dementia compared with asymptomatic individuals. The study also explored unsupervised blood collection, finding high concordance between supervised and self-collected samples. These findings underscore the potential of dried blood collection and capillary blood as a minimally invasive, scalable approach for AD biomarker testing in research settings. Yet, further refinement of collection and analytical protocols is needed to fully translate this approach to be viable and useful as a clinical tool.
000285353 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000285353 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000285353 650_7 $$2NLM Chemicals$$aBiomarkers
000285353 650_7 $$2NLM Chemicals$$atau Proteins
000285353 650_7 $$2NLM Chemicals$$aNeurofilament Proteins
000285353 650_7 $$2NLM Chemicals$$aneurofilament protein L
000285353 650_7 $$2NLM Chemicals$$aGlial Fibrillary Acidic Protein
000285353 650_7 $$2NLM Chemicals$$aMAPT protein, human
000285353 650_2 $$2MeSH$$aHumans
000285353 650_2 $$2MeSH$$aAlzheimer Disease: blood
000285353 650_2 $$2MeSH$$aAlzheimer Disease: diagnosis
000285353 650_2 $$2MeSH$$aAlzheimer Disease: pathology
000285353 650_2 $$2MeSH$$aDried Blood Spot Testing: methods
000285353 650_2 $$2MeSH$$aBiomarkers: blood
000285353 650_2 $$2MeSH$$aBiomarkers: cerebrospinal fluid
000285353 650_2 $$2MeSH$$aFemale
000285353 650_2 $$2MeSH$$atau Proteins: blood
000285353 650_2 $$2MeSH$$aMale
000285353 650_2 $$2MeSH$$aAged
000285353 650_2 $$2MeSH$$aNeurofilament Proteins: blood
000285353 650_2 $$2MeSH$$aGlial Fibrillary Acidic Protein: blood
000285353 650_2 $$2MeSH$$aAged, 80 and over
000285353 650_2 $$2MeSH$$aMiddle Aged
000285353 650_2 $$2MeSH$$aPhosphorylation
000285353 7001_ $$00000-0001-7684-6318$$aMontoliu-Gaya, Laia$$b1
000285353 7001_ $$00000-0002-9777-0559$$aBrum, Wagner S$$b2
000285353 7001_ $$aVávra, Jakub$$b3
000285353 7001_ $$aYakoub, Yara$$b4
000285353 7001_ $$aWeninger, Haley$$b5
000285353 7001_ $$aBraun-Wohlfahrt, Luisa Sophie$$b6
000285353 7001_ $$aSimrén, Joel$$b7
000285353 7001_ $$00000-0003-2617-3009$$aBoada, Mercé$$b8
000285353 7001_ $$00000-0003-2633-2495$$aRuiz, Agustín$$b9
000285353 7001_ $$aCano, Amanda$$b10
000285353 7001_ $$aOrellana, Adelina$$b11
000285353 7001_ $$aValero, Sergi$$b12
000285353 7001_ $$aCañada, Laia$$b13
000285353 7001_ $$aTantinya, Natalia$$b14
000285353 7001_ $$aNogales, Ana Belen$$b15
000285353 7001_ $$aSanz-Cartagena, Pilar$$b16
000285353 7001_ $$00000-0002-5168-2975$$aDittrich, Anna$$b17
000285353 7001_ $$aSkoog, Ingmar$$b18
000285353 7001_ $$aSander-Long, Millie$$b19
000285353 7001_ $$00000-0003-0022-5632$$aBallard, Clive$$b20
000285353 7001_ $$aRichards, Megan$$b21
000285353 7001_ $$aO'Leary, Mary$$b22
000285353 7001_ $$00000-0001-7374-2919$$aClemmensen, Frederikke Kragh$$b23
000285353 7001_ $$aWandall, Hannah H D$$b24
000285353 7001_ $$aAltomare, Daniele$$b25
000285353 7001_ $$aCantoni, Valentina$$b26
000285353 7001_ $$aStomrud, Erik$$b27
000285353 7001_ $$00000-0002-9267-1930$$aPalmqvist, Sebastian$$b28
000285353 7001_ $$00000-0002-2568-5478$$aLleo, Alberto$$b29
000285353 7001_ $$00000-0002-3819-3245$$aAlcolea, Daniel$$b30
000285353 7001_ $$aCarmona Iragui, Maria$$b31
000285353 7001_ $$aHernandez, Aida Sanjuan$$b32
000285353 7001_ $$aBenejam, Bessy$$b33
000285353 7001_ $$00000-0002-9748-8465$$aVidela Toro, Laura$$b34
000285353 7001_ $$aSingh, Alpana$$b35
000285353 7001_ $$aDenkinger, Marisa N$$b36
000285353 7001_ $$00000-0002-5461-162X$$aSimonsen, Anja Hviid$$b37
000285353 7001_ $$aKern, Silke$$b38
000285353 7001_ $$aCorbett, Anne$$b39
000285353 7001_ $$00000-0002-1340-638X$$aFortea, Juan$$b40
000285353 7001_ $$00000-0003-0996-1062$$aHonigberg, Lee$$b41
000285353 7001_ $$00000-0001-9340-9814$$aBorroni, Barbara$$b42
000285353 7001_ $$00000-0001-8467-7286$$aHansson, Oskar$$b43
000285353 7001_ $$aMorató, Xavier$$b44
000285353 7001_ $$00000-0002-1890-4193$$aBlennow, Kaj$$b45
000285353 7001_ $$00000-0003-3930-4354$$aZetterberg, Henrik$$b46
000285353 7001_ $$00000-0002-3579-8804$$aAshton, Nicholas J$$b47
000285353 773__ $$0PERI:(DE-600)1484517-9$$a10.1038/s41591-025-04080-0$$gVol. 32, no. 2, p. 599 - 608$$n2$$p599 - 608$$tNature medicine$$v32$$x1078-8956$$y2026
000285353 8564_ $$uhttps://pub.dzne.de/record/285353/files/DZNE-2026-00219.pdf$$yRestricted
000285353 8564_ $$uhttps://pub.dzne.de/record/285353/files/DZNE-2026-00219.pdf?subformat=pdfa$$xpdfa$$yRestricted
000285353 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9003257$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000285353 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000285353 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2025-01-06$$wger
000285353 915__ $$0StatID:(DE-HGF)3003$$2StatID$$aDEAL Nature$$d2025-01-06$$wger
000285353 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-06
000285353 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-06
000285353 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-06
000285353 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-06
000285353 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-06
000285353 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-01-06
000285353 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-06
000285353 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-06
000285353 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-06
000285353 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-06
000285353 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNAT MED : 2022$$d2025-01-06
000285353 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-06
000285353 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-06
000285353 915__ $$0StatID:(DE-HGF)9980$$2StatID$$aIF >= 80$$bNAT MED : 2022$$d2025-01-06
000285353 9201_ $$0I:(DE-2719)1011305$$kAG Schneider$$lTranslational Dementia Research (Bonn)$$x0
000285353 980__ $$ajournal
000285353 980__ $$aEDITORS
000285353 980__ $$aVDBINPRINT
000285353 980__ $$aI:(DE-2719)1011305
000285353 980__ $$aUNRESTRICTED